Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Baxter
AstraZeneca
Moodys
Johnson and Johnson

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Ozanimod

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Ozanimod?

Ozanimod is an investigational drug.

There have been 13 clinical trials for Ozanimod. The most recent clinical trial was a Phase 1 trial, which was initiated on February 27th 2018.

The most common disease conditions in clinical trials are Crohn Disease, Sclerosis, and Multiple Sclerosis. The leading clinical trial sponsors are Celgene and [disabled in preview].

There are eight US patents protecting this investigational drug and one hundred and sixteen international patents.

Recent Clinical Trials for Ozanimod
TitleSponsorPhase
Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)CelgenePhase 3
Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active MetabolitesCelgenePhase 1
To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative ColitisCelgenePhase 2/Phase 3

See all Ozanimod clinical trials

Clinical Trial Summary for Ozanimod

Top disease conditions for Ozanimod
Top clinical trial sponsors for Ozanimod

See all Ozanimod clinical trials

US Patents for Ozanimod

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ozanimod   Start Trial Kinase inhibitors Respivert Limited (High Wycombe, Buckinghamshire, GB) Topivert Pharma Limited (London, GB)   Start Trial
Ozanimod   Start Trial Kinase inhibitors Respivert Limited (N/A) Topivert Pharma Limited (London, GB)   Start Trial
Ozanimod   Start Trial Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis CELGENE INTERNATIONAL II S RL (Couvet, CH)   Start Trial
Ozanimod   Start Trial Sphingosine pathway modulating compounds for the treatment of cancers Enzo Biochem, Inc. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ozanimod

Drugname Country Document Number Estimated Expiration Related US Patent
Ozanimod Australia 2017245888 2036-04-06   Start Trial
Ozanimod Brazil 112018067552 2036-04-06   Start Trial
Ozanimod Canada 3015978 2036-04-06   Start Trial
Ozanimod China 109071505 2036-04-06   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Dow
Harvard Business School
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.